Pharma Pushes For Stronger ‘March In’ Rule Despite Changing Political Dynamics, COVID Complications

 
• By Sarah Karlin-Smith

With COVID-19 drawing new attention to the government’s investment in R&D and high drug prices, lower drug pricing advocates are optimistic the Biden team will a Trump-era attempt to carve out a medication’s price from patent breaking criteria. The drug industry isn’t just defending Trump’s plan – its trying to strengthen it.

patent license agreement
The Biden administration will have to review more than 80,000 comments on a proposed rule impacting patent rights • Source: Shutterstock

More from Legal & IP

More from Pink Sheet